https://www.live-feeds.com/feed/abbvie-reports-third-quarter-2026-financial-resultsContinuously updated, source-cited coverage. https://www.live-feeds.com/feed/abbvie-reports-third-quarter-2026-financial-resultshttps://www.live-feeds.com/feed/abbvie-reports-third-quarter-2026-financial-results#u178645Thu, 05 Nov 2026 20:42:24 +0000AbbVie reported third-quarter 2026 net revenue of US$17.4b and basic earnings per share of US$2.38, beating estimates and prompting the company to lift its full-year revenue and adjusted earnings guidance. Growth was driven primarily by the company's neuroscience and immunology portfolios, specifically the performance of Skyrizi and Rinvoq. While the stock reached an all-time high and rose to approximately US$294.83 following the release, some reports indicate the stock also experienced a dip despite the positive earnings print. GAAP diluted EPS rose over 100.0 percent to $2.37, while adj